DEF: Kalaris Therapeutics Sets 2025 Annual Meeting Agenda, Details Post-Merger Governance and Executive Compensation

Kalaris Therapeutics, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on August 12, 2025, where shareholders will vote on director elections and auditor ratification, following its recent merger with Legacy Kalaris Tx, Inc.

Summary

• The 2025 Annual Meeting of Stockholders will be held exclusively via the Internet on Tuesday, August 12, 2025, at 11:30 a.m. Eastern Time.
• Stockholders will vote on the election of two Class II directors, Srinivas Akkaraju, M.D., Ph.D., and Andrew Oxtoby, each to serve for a three-year term expiring at the 2028 annual meeting.
• Stockholders will also vote on the ratification of the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The company completed its merger with privately held Legacy Kalaris Tx, Inc. on March 18, 2025, and subsequently changed its name from AlloVir, Inc. to Kalaris Therapeutics, Inc.
• Following the merger, the company became a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for prevalent retinal disease.
• A 1-for-23 reverse stock split of the company's common stock became effective on January 15, 2025.
• As of June 25, 2025, there were 18,702,418 shares of common stock outstanding, with a quorum requiring approximately 9,351,210 shares.
• Samsara BioCapital, L.P. beneficially owns 61.21% of the outstanding common stock, classifying the company as a 'controlled company' under Nasdaq rules.

Sentiment

Score: 6

Explanation: The document is a standard proxy statement detailing corporate governance, executive compensation, and the upcoming annual meeting following a significant merger. While it doesn't present financial performance, the successful completion of the merger and the clear outline of future governance and strategic focus (retinal disease) suggest a stable, forward-looking operational status. The disclosure of past financial challenges (AlloVir not meeting 2023 goals) is balanced by the new strategic direction.

Positives

• The virtual meeting format is designed to enable greater stockholder attendance and participation from any location globally.
• Providing proxy materials over the Internet expedites stockholders' receipt of materials, lowers costs, and reduces environmental impact.
• The board of directors believes that separating the roles of Chair and Chief Executive Officer allows the CEO to focus on day-to-day business while the Chair provides independent oversight.
• The company believes its executive compensation program does not encourage excessive or unnecessary risk-taking, as it is designed to align executive officers and employees with both short-term and long-term strategic goals.
• A new non-employee director compensation policy has been adopted to attract and retain high-caliber non-employee directors.

Negatives

• AlloVir did not achieve its corporate goals for 2023, resulting in no annual cash incentive bonuses for its named executive officers for that year.
• Immediately prior to the merger, all unexercised and outstanding AlloVir options with an exercise price per share equal to or greater than $92.00 (after giving effect to the Reverse Stock Split) were cancelled for no consideration.

Risks

• The company faces risks described under the caption 'Risk Factors' in Exhibit 99.2 to its Current Report on Form 8-K filed on March 18, 2025, and its Annual Report on Form 10-K for the year ended December 31, 2024.
• One Form 4 for Brett Hagen was filed late on January 2, 2024, reporting a transaction on December 27, 2023, indicating a past instance of non-compliance with Section 16(a) reporting requirements.
• Purchasers who failed to buy the entire Subsequent Tranche Closings Amount in the Additional Permitted Bridge Financing would have faced penalties, including automatic conversion of Series B-2 Preferred Stock into common stock at a less favorable rate, termination of Major Investor status, and loss of board observer rights.

Future Outlook

The company, following its merger, is now a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics aimed at becoming the standard of care for prevalent retinal disease for which there is a major unmet medical need. As an emerging growth company and a smaller reporting company, it plans to continue relying on exemptions from certain disclosure requirements.

Management Comments

• The board of directors believes that hosting a virtual meeting will enable greater stockholder attendance and participation from any location around the world.
• The board of directors believes that having separate positions for the Chair of the board and Chief Executive Officer is the appropriate leadership structure for the company at this time and demonstrates its commitment to good corporate governance.
• The board of directors believes that full and open communication between management and the board of directors is essential for effective risk management and oversight.
• The company believes that equity grants provide its executive officers and other key employees with a strong link to its long-term performance, create an ownership culture, and help to align the interests of its executive officers, other key employees, and stockholders.

Industry Context

The company has undergone a significant strategic pivot, transitioning from a late-stage clinical allogenic T cell immunotherapy company (AlloVir) to a clinical-stage biopharmaceutical company focused on prevalent retinal disease. This shift positions Kalaris Therapeutics in a specialized and potentially high-growth segment of the biopharmaceutical industry, addressing a specific area of unmet medical need. The merger and subsequent re-focus indicate a strategic realignment to leverage new therapeutic opportunities within ophthalmology.

Comparison to Industry Standards

• The company's status as an 'emerging growth company' and 'smaller reporting company' allows it to utilize reduced disclosure obligations, which is a common practice for companies of similar size and stage, differentiating its reporting from larger, more established pharmaceutical or biotechnology firms.
• The separation of the roles of Board Chair (David Hallal) and Chief Executive Officer (Andrew Oxtoby) aligns with best practices in corporate governance, often seen in more mature companies, promoting independent oversight of management.
• The adoption of a compensation recovery policy (Clawback Policy) in accordance with SEC and Nasdaq listing rules demonstrates adherence to modern corporate governance standards, comparable to those found in many publicly traded companies.
• The detailed disclosure of related party transactions, particularly with Samsara BioCapital, L.P. and ElevateBio, highlights the company's compliance with transparency requirements, which is standard for public companies with significant investor relationships.

Management Changes

Corporate Governance

Related Party Transactions

• The company completed a merger with privately held Legacy Kalaris Tx, Inc. on March 18, 2025, issuing 13,634,744 shares of common stock to Legacy Kalaris securityholders.
• Samsara BioCapital, L.P. (a greater than 5% beneficial owner and affiliate of directors Srinivas Akkaraju and Michael Dybbs) participated in multiple financings of Legacy Kalaris, including convertible notes (December 2021, December 2022, May 2023, March 2024) and preferred stock (Series A, Series B-1, Series B-2), and a Simple Agreement for Future Equity (SAFE).
• Samsara BioCapital, L.P. provided in-kind research and development and general and administrative services to Legacy Kalaris since its inception, and cash-compensated general and administrative services since April 2022 under a Business Services Agreement, which remains in effect post-merger.
• In July 2024, Legacy Kalaris entered into a Royalty Agreement with Samsara LP, redeeming 50,000 shares of common stock in exchange for a low single-digit percentage tiered royalty on net sales of products developed using technology licensed from the University of California, San Diego.
• AlloVir had a Shared Services Agreement with ElevateBio (a former greater than 5% stockholder, with affiliates David Hallal, Vikas Sinha, and Morana Jovan-Embiricos serving as directors/executives), which provided various services and terminated on May 1, 2024.
• AlloVir was party to a Development and Manufacturing Services Agreement (BaseCamp Agreement) with BaseCamp (owned by ElevateBio), which provided laboratory and manufacturing services and expired on January 1, 2024.
• AlloVir had a services agreement with Marker Therapeutics, Inc. (co-founded by Juan Vera, a former director/executive officer), which was inherited by CellReady LLC in June 2023.
• Napoleone Ferrara, M.D. (a current director) has a consulting agreement with the company since July 2021, earning $50,000 per year for scientific, technical, and medical advice, unrelated to his board service.
• The Thomas Elden 2021 Ajax Trust (affiliated with Samir Patel, a former Legacy Kalaris board member) participated in the Series B-2 Preferred Stock financing and the November 2024/January 2025 Bridge Notes financings.

Stakeholder Impact

• Shareholders: Directly impacted by the merger, reverse stock split, and the company's new strategic focus on retinal disease. They are invited to vote on director elections and auditor ratification, influencing corporate governance. Executive and director compensation policies are also relevant to shareholder interests.
• Employees: Executive compensation, including base salaries, bonuses, equity incentives, and severance arrangements, directly impacts the company's executive officers and other key employees. The merger led to significant changes in executive roles and compensation structures for former AlloVir executives.
• Customers/Patients: The company's strategic shift to developing therapeutics for prevalent retinal disease indicates a new focus on addressing unmet medical needs in this patient population, potentially leading to new product offerings.
• Suppliers/Partners: Existing and past relationships with entities like Samsara LP, ElevateBio, Marker Therapeutics, and CellReady LLC highlight the company's reliance on external services for research, development, manufacturing, and administrative support.
• Creditors: The detailed history of convertible notes and bridge financings indicates the company's reliance on debt and equity financing, which impacts its financial obligations and capital structure.

Next Steps

• Stockholders will consider and vote on the election of two Class II directors and the ratification of the selection of Deloitte & Touche LLP at the 2025 Annual Meeting on August 12, 2025.
• Final voting results from the Annual Meeting will be tallied by the inspector of election and published in a current report on Form 8-K within four business days after the meeting.
• The company will continue its focus on developing and commercializing innovative therapeutics for prevalent retinal disease.
• The 2020 Plan and ESPP have evergreen provisions allowing for an annual increase in available shares on the first day of each fiscal year.
• Beginning with the 2026 annual meeting of stockholders, each non-employee director will be granted an option to purchase 9,000 shares of common stock annually.
• Stockholders wishing to submit proposals for inclusion in the proxy statement for the 2026 annual meeting must do so by March 3, 2026.
• Stockholders wishing to present proposals not included in the proxy statement at the 2026 annual meeting must provide notice between April 14, 2026, and May 14, 2026.
• Stockholders intending to solicit proxies in support of director nominees other than the company's nominees must provide notice by June 13, 2026.

Key Dates

Keywords

Kalaris Therapeutics, AlloVir, SEC filing, Proxy Statement, Annual Meeting, Corporate Governance, Biopharmaceutical, Retinal Disease, Merger, Reverse Stock Split, Executive Compensation, Director Compensation, Related Party Transactions, Nasdaq, Controlled Company, Audit Committee, Deloitte & Touche LLP